Agenus Announces $6.5 Million Registered Direct At the Market Offering
LEXINGTON, Mass. -- September 18, 2013
Agenus Inc. (Nasdaq: AGEN) today announced that it has received commitments
from institutional investors to purchase an aggregate of approximately $6.5
million of its common stock at the market.
Agenus entered into a definitive purchase agreement with these investors
pursuant to which it agreed to sell an aggregate of 2,166,667 shares of its
common stock and warrants to purchase up to approximately 650,000 additional
shares of its common stock. Each unit, consisting of one share of common stock
and a warrant to purchase 0.3 of a share of common stock, will be sold for a
purchase price of $3.00. The warrants to purchase additional shares will be
exercisable at a price of $3.75 per share beginning six months following
issuance and will expire five years from the date on which the warrants are
initially exercisable. The closing of the offering is expected to take place
on or about September 23, 2013, subject to the satisfaction of customary
H.C. Wainwright & Co., LLC acted as exclusive placement agent in connection
with the offering.
A shelf registration statement (File No. 333-185657) relating to the shares
issued in the offering has been filed with and declared effective by the
Securities and Exchange Commission (the “SEC”). A prospectus supplement
relating to the offering will be filed by Agenus with the SEC. Copies of the
prospectus supplement, together with the accompanying prospectus, can be
obtained at the SEC’s website at http://www.sec.gov, from request at H.C.
Wainwright & Co., LLC by e-mailing firstname.lastname@example.org, or from Agenus Inc.,
3 Forbes Road, Lexington, Massachusetts 02421.
This press release does not constitute an offer to sell or the solicitation of
an offer to buy any securities of Agenus in this offering. There shall not be
any offer, solicitation of an offer to buy, or sale of securities in any state
or jurisdiction in which such an offering, solicitation, or sale would be
unlawful prior to registration or qualification under the securities laws of
any such state or jurisdiction. Any offering will be made only by means of a
prospectus, including a prospectus supplement, forming a part of the effective
Agenus Inc. is a biotechnology company working to develop treatments for
cancers and infectious diseases. The company is focused on immunotherapeutic
products based on strong platform technologies with multiple product
candidates advancing through the clinic, including several product candidates
that have advanced into late-stage clinical trials through corporate partners.
Between Agenus and its partners, 23 programs are in clinical development.
Statements made in this press release include forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended, regarding,
but not limited to, the amount Agenus expects to receive from the offering and
the timing for the closing of the offering. Forward-looking statements can be
identified by the use of words such as “may,” “will,” “plan,” “should,”
“expect,” “anticipate,” “estimate,” “continue,” or comparable terminology.
Such forward-looking statements are inherently subject to certain risks,
trends and uncertainties, many of which Agenus cannot predict with accuracy
and some of which Agenus might not even anticipate, and involve factors that
may cause actual results to differ materially from those projected or
suggested. These risks and uncertainties include, among others, the factors
described under the Risk Factors section of Agenus’ Quarterly Report on Form
10-Q for the quarter ended June 30, 2013, which was filed with the SEC on
August 9, 2013. Agenus cautions investors not to place considerable reliance
on the forward-looking statements contained in this release. These statements
speak only as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements.
Media and Investor Contact:
Jonae R. Barnes, 617-818-2985
Investor Relations and
Press spacebar to pause and continue. Press esc to stop.